(Q33407265)

English

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

B-cell non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Paul Mouncey

6

0 references

object named as

Eliza A Hawkes

2

0 references

object named as

John A Radford

9

0 references

object named as

Peter Johnson

14

0 references

David Cunningham

object named as

David Cunningham

1

0 references

Kirit M. Ardeshna

8

object named as

Kirit M Ardeshna

1 reference

Europe PubMed Central

26 July 2017

16

object named as

David Linch

1 reference

Europe PubMed Central

26 July 2017

4

object named as

Wendi Qian

1 reference

Europe PubMed Central

26 July 2017

author name string

Andrew Jack

3

1 reference

Europe PubMed Central

26 July 2017

Paul Smith

5

1 reference

Europe PubMed Central

26 July 2017

Christopher Pocock

7

1 reference

Europe PubMed Central

26 July 2017

Andrew McMillan

10

1 reference

Europe PubMed Central

26 July 2017

John Davies

11

1 reference

Europe PubMed Central

26 July 2017

Deborah Turner

12

1 reference

Europe PubMed Central

26 July 2017

Anton Kruger

13

1 reference

Europe PubMed Central

26 July 2017

Joanna Gambell

15

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

22 April 2013

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

381

1 reference

Europe PubMed Central

26 July 2017

9880

1 reference

Europe PubMed Central

26 July 2017

1817-1826

1 reference

Europe PubMed Central

26 July 2017

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo I

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensified chemotherapy for diffuse large B-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Stromal gene signatures in large-B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960313-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(13)60313-X

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33407265&oldid=1859423380"